



For Metastatic Non-Small Cell Lung Cancer (NSCLC)

Your Guide

WHAT IS TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat:

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

- **TECENTRIQ may be used alone as your first treatment when your lung cancer:**
 - has spread or grown, **and**
 - your cancer tests positive for “high PD-L1”, **and**
 - your tumor does not have an abnormal “EGFR” or “ALK” gene.
- **TECENTRIQ may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer:**
 - has spread or grown, **and**
 - is a type called “non-squamous NSCLC”, **and**
 - your tumor does not have an abnormal “EGFR” or “ALK” gene.
- **TECENTRIQ may be used with the medicines paclitaxel protein-bound and carboplatin as your first treatment when your lung cancer:**
 - has spread or grown, **and**
 - is a type called “non-squamous NSCLC”, **and**
 - your tumor does not have an abnormal “EGFR” or “ALK” gene.
- **TECENTRIQ may be used alone when your lung cancer:**
 - has spread or grown, **and**
 - you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
 - If your tumor has an abnormal “EGFR” or “ALK” gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

It is not known if TECENTRIQ is safe and effective when used in children for the treatment of NSCLC.

SELECT IMPORTANT SAFETY INFORMATION

TECENTRIQ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Please see pages 16-18 and full [Prescribing Information](#) for additional Important Safety Information.

This guide will help explain how TECENTRIQ is thought to work, and will provide Important Safety Information. This brochure also includes a list of financial resources that might be available. Read up on some practical treatment tips that may be helpful for you and your support circle.

This brochure is not intended to replace a conversation with your doctor.

Here for you

Dealing with cancer can be difficult. It's okay to feel overwhelmed or unsure of what the future looks like. There may be ups and downs ahead. This guide is here to help you navigate your journey and provide you with support. Learn more about metastatic non-small cell lung cancer (NSCLC) and how TECENTRIQ may help. This is a great starting point to help you begin to prepare for the next steps ahead.

For more information visit



TECENTRIQ.com/NSCLCinfo

or call the Patient Resource Center:



1 (877) GENENTECH (1-877-436-3683)

The Patient Resource Center is a general help line for questions related to TECENTRIQ for patients and caregivers and is not meant to be medical advice or replace the advice of your healthcare team.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ[®]**
atezolizumab 840 mg | 1200 mg
INJECTION FOR IV USE

Getting Started

This brochure was made to help answer questions you may have about metastatic non-small cell lung cancer and TECENTRIQ.

Remember to talk to your healthcare team throughout the process. They can answer any questions you may have and make sure the treatments you receive are right for you. Find information on the following:

pages 4-5

**What is non-small cell lung cancer?
What is TECENTRIQ?**

page 6

**Understanding cancer cells & PD-L1
How is TECENTRIQ thought to work?**

pages 8-9

What are the potential benefits of TECENTRIQ + other medicines?

pages 10-11

**What are the potential benefits of TECENTRIQ alone?
How is TECENTRIQ given?**

page 12

Financial resources

pages 14-15

**Additional financial resources
Connecting with care partners**

pages 16-18

Important Safety Information about TECENTRIQ

page 19

Glossary

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 2000 mg
INJECTION FOR IV USE

WHAT IS NON-SMALL CELL LUNG CANCER?

Lung cancer occurs when the cells in your lungs start to grow unusually or uncontrollably. The most common type of lung cancer is called non-small cell lung cancer (NSCLC). With this type of lung cancer, unusual growth takes place inside your lungs or the lining of the airways. As more cancer cells grow they can form into a tumor. As the disease advances, it may spread to the areas around your lungs or to other parts of your body. This is called metastatic non-small cell lung cancer.

WHAT ARE SOME OF THE SYMPTOMS OF NSCLC?

The most common symptoms of lung cancer may include:

- A cough that does not go away or gets worse
- Coughing up blood or rust-colored spit
- Chest pain that may get worse when taking deep breaths, coughing or laughing
- Hoarseness
- Weight loss and loss of appetite
- Shortness of breath
- Feeling tired or weak
- Infections such as bronchitis and pneumonia that don't go away or keep coming back
- New onset of wheezing

When lung cancer spreads to distant organs (metastatic lung cancer), it can cause other symptoms which may include:

- Bone pain (like pain in the back or hips)
- Difficulty swallowing
- Swelling of the face
- Bulging veins on the neck and head
- Lumps in the neck or above the collarbone
- Yellowing of the skin and eyes
- Headache
- Weakness or numbness of an arm or a leg
- Dizziness
- Balance problems
- Seizures

Experiencing these symptoms does not necessarily mean you have lung cancer. However, it is very important to talk to your healthcare team if you experience any of these symptoms. Your healthcare team has the knowledge and the tools needed to make the appropriate diagnosis.

**FOR MORE INFORMATION ABOUT TECENTRIQ
TALK TO YOUR HEALTHCARE TEAM**

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1000 mg
INJECTION FOR IV USE



WHAT IS TECENTRIQ?

TECENTRIQ is a prescription medicine used to treat:

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

- **TECENTRIQ may be used alone as your first treatment when your lung cancer:**
 - has spread or grown, **and**
 - your cancer tests positive for “high PD-L1”, **and**
 - your tumor does not have an abnormal “EGFR” or “ALK” gene.
- **TECENTRIQ may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer:**
 - has spread or grown, **and**
 - is a type called “non-squamous NSCLC”, **and**
 - your tumor does not have an abnormal “EGFR” or “ALK” gene.
- **TECENTRIQ may be used with the medicines paclitaxel protein-bound and carboplatin as your first treatment when your lung cancer:**
 - has spread or grown, **and**
 - is a type called “non-squamous NSCLC”, **and**
 - your tumor does not have an abnormal “EGFR” or “ALK” gene.
- **TECENTRIQ may be used alone when your lung cancer:**
 - has spread or grown, **and**
 - you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
 - If your tumor has an abnormal “EGFR” or “ALK” gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

It is not known if TECENTRIQ is safe and effective when used in children for the treatment of NSCLC.

SELECT IMPORTANT SAFETY INFORMATION

Possible serious side effects with TECENTRIQ include, but are not limited to, lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, skin problems, problems in other organs, severe infusion reactions, and complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic).

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.


TECENTRIQ[®]
 atezolizumab 640 mg / 1000 mg
INJECTION FOR IV USE

UNDERSTANDING CANCER CELLS & PD-L1

Your immune system helps to protect you against infection and disease. It does this through a collection of specialized organs and cells. Normally, your immune system is able to detect and remove abnormal cells, such as cancer cells.



Some cancer cells can go undetected by your immune system. One way they can go undetected is through a protein called programmed death-ligand 1, or PD-L1. This protein is found on many cells, including cancer cells. PD-L1 on cancer cells may bind to your immune cells. When it does this, the cancer cell is seen as a healthy cell. This may prevent your immune system from being able to recognize and attack your cancer.

HOW IS TECENTRIQ THOUGHT TO WORK?

TECENTRIQ is a cancer immunotherapy that can help reactivate the immune system so it can recognize cancer cells in the body. TECENTRIQ is an anti-PD-L1 antibody, meaning it is designed to block PD-L1. By blocking PD-L1, TECENTRIQ is thought to reveal cancer cells. This process helps your immune system recognize, target, and attack your cancer. TECENTRIQ may also affect normal cells.

SELECT IMPORTANT SAFETY INFORMATION

TECENTRIQ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 600 mg | 1000 mg
INJECTION FOR IV USE



Please see full [Prescribing Information](#)
and additional [Important Safety Information](#)
throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1000 mg
INJECTION FOR IV USE

WHAT ARE THE POTENTIAL BENEFITS OF TECENTRIQ + OTHER MEDICINES?

Results from a clinical trial of TECENTRIQ + other medicines (bevacizumab + carboplatin + paclitaxel) that included 696 people with metastatic non-squamous non-small cell lung cancer (nsqNSCLC) with no abnormal EGFR or ALK gene:

TECENTRIQ WITH BEVACIZUMAB + CHEMOTHERAPY*

HELPED PEOPLE LIVE LONGER

Median overall survival (OS)[†]



[†]Median overall survival (OS)=the length of time from the start of treatment in a clinical trial that half of the patients are still alive.

DELAYED DISEASE PROGRESSION

Median progression-free survival (PFS): The amount of time that half the people lived without their tumors growing or spreading was 7 months for those not taking TECENTRIQ. That time is compared with 8.5 months for those taking TECENTRIQ with bevacizumab + chemotherapy.*

*Chemotherapy=carboplatin + paclitaxel.

TECENTRIQ may not work for everyone.

SELECT IMPORTANT SAFETY INFORMATION

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Lung problems

- cough
- shortness of breath
- chest pain

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 640 mg / 1000 mg
INJECTION FOR IV USE

WHAT ARE THE POTENTIAL BENEFITS OF TECENTRIQ + OTHER MEDICINES?

Results from a clinical trial of TECENTRIQ that included 681 people with metastatic nsqNSCLC with no abnormal EGFR or ALK gene:

TECENTRIQ IN ADDITION TO CARBOPLATIN + NAB-PAC[‡]

HELPED PEOPLE LIVE LONGER

Median overall survival (OS)[†]



[†]Median overall survival (OS)=the length of time from the start of treatment in a clinical trial that half of the patients are still alive.

DELAYED DISEASE PROGRESSION

Median progression-free survival (PFS): The amount of time that half the people lived without their tumors growing or spreading was 6.5 months for those not taking TECENTRIQ. That time is compared with 7.2 months for those taking TECENTRIQ in addition to carboplatin + nab-pac.[‡]

[‡]Nab-paclitaxel (nab-pac) is a chemotherapy also referred to as paclitaxel protein-bound. TECENTRIQ may not work for everyone.

SELECT IMPORTANT SAFETY INFORMATION

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Intestinal problems

- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1200 mg
INJECTION FOR IV USE

WHAT ARE THE POTENTIAL BENEFITS OF TECENTRIQ ALONE?

Results from a clinical trial of TECENTRIQ, that included 205 people with metastatic non-small cell lung cancer (mNSCLC) who tested positive for high PD-L1 with no abnormal EGFR or ALK gene and had not been previously treated:

TECENTRIQ AS A FIRST TREATMENT

HELPED PEOPLE LIVE LONGER

Median overall survival (OS)*



*Median overall survival (OS)=the length of time from the start of treatment in a clinical trial that half of the patients are still alive.

[†]For non-squamous NSCLC, chemotherapy consisted of either cisplatin or carboplatin followed by pemetrexed. For squamous NSCLC, chemotherapy consisted of cisplatin/carboplatin + gemcitabine.

ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor.

Results from a clinical trial of TECENTRIQ that included 850 people with previously treated mNSCLC:

TECENTRIQ AFTER CHEMOTHERAPY

HELPED PEOPLE LIVE LONGER

Median overall survival (OS)*



*Median overall survival (OS)=the length of time from the start of treatment in a clinical trial that half of the patients are still alive.

[‡]Docetaxel.

TECENTRIQ may not work for everyone.

SELECT IMPORTANT SAFETY INFORMATION

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Liver problems

- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 600 mg / 1000 mg
INJECTION FOR IV USE



HOW IS TECENTRIQ GIVEN?

Your healthcare provider will give you TECENTRIQ into your vein through an intravenous (IV) line. They will also decide how long you may be on treatment. If at any point the disease progresses or treatment can't be tolerated, infusions will be stopped.

LENGTH OF INFUSION TIME

INITIAL INFUSION: 60 MINUTES

FOLLOWING INFUSIONS: 30 MINUTES



The first infusion will be given over 60 minutes. If it's well tolerated, all following TECENTRIQ infusions may be given over 30 minutes. If TECENTRIQ is one part of your treatment, infusion time may be longer.

FLEXIBLE INFUSION SCHEDULE

EVERY 2 WEEKS



EVERY 3 WEEKS



EVERY 4 WEEKS



TECENTRIQ has flexible dosing options and can be given every 2, 3, or 4 weeks. Depending on your treatment plan, you may need to see your doctor more frequently. Your doctor will decide which treatment schedule is best for you.[§]

[§]TECENTRIQ will be given as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks.

SELECT IMPORTANT SAFETY INFORMATION

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Kidney problems

- decrease in your amount of urine
- swelling of your ankles
- blood in your urine
- loss of appetite

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

TECENTRIQ[®]
atezolizumab
840 mg | 1200 mg
INJECTION FOR IV USE

COMMITTED TO HELPING YOU FIND ASSISTANCE OPTIONS FOR TECENTRIQ

If you are worried about paying for TECENTRIQ, we can help you understand options that may help you. We can find out how much it will cost. We can also help you understand if there are options to help you pay for it.

TECENTRIQ ACCESS SOLUTIONS

TECENTRIQ Access Solutions is committed to helping you get the Genentech medicine your doctor prescribed.

At [Genentech-Access.com/TECENTRIQ/patients](https://www.genentech-access.com/TECENTRIQ/patients), you can:

- Find out what we offer
- Learn what to expect from GENENTECH
- Connect with financial assistance options

GENENTECH PATIENT FOUNDATION

The Genentech Patient Foundation provides free TECENTRIQ to people who need it. If you have health insurance, you should try to get other types of financial assistance, if available. You also need to meet income requirements. If you do not have insurance, or if your insurance does not cover your TECENTRIQ, you must meet a different set of income requirements. Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of information submitted.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 2000 mg
INJECTION FOR IV USE



Please see full [Prescribing Information](#)
and additional [Important Safety Information](#)
throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 2000 mg
INJECTION FOR IV USE

THE GENENTECH ONCOLOGY CO-PAY ASSISTANCE PROGRAM

The Genentech Oncology Co-pay Program helps you if you have commercial health insurance and meet other eligibility criteria.

<p>NO INCOME REQUIREMENTS</p>	<p>PATIENTS PAY AS LITTLE AS \$0 FOR TECENTRIQ</p>	<p>ANNUAL BENEFIT LIMIT OF CO-PAY PROGRAM IS \$25k</p>
--	---	---

No physical card needed; patients simply need their Member ID.

To learn more about the Genentech Oncology Co-pay Assistance Program, call (855) MY-COPAY (855-692-6729) or visit copayassistancenow.com

The Co-pay Program is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. Patients using Medicare, Medicaid or any other federal or state government program (collectively, "Government Programs") to pay for their Genentech medicine are not eligible.

Under the Program, the patient may pay a co-pay. The final amount owed by a patient may be as little as \$0 for the Genentech medicine (see Program specific details). The total patient out-of-pocket cost is dependent on the patient's health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient's out-of-pocket expenses for the cost associated with the Genentech medicine.

All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. No party may seek reimbursement for all or any part of the benefit received through the Program. The Program is intended for the patient. Only the patient using the Program may receive the funds made available through the Program.

Please visit copayassistancenow.com for the full list of terms and conditions.

Please see full [Prescribing Information](#) and additional Important Safety Information throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1200 mg
INJECTION FOR IV USE



The Program is not intended for third parties who reduce the amount available to the patient or take a portion for their own purposes. Patients with health plans that redirect Genentech Program assistance intended for patient out-of-pocket costs may be subject to alternate Program benefit structures. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.

Additional terms and conditions apply. Please visit the Co-pay Program website for the full list of Terms and Conditions.

CONNECTING WITH CARE PARTNERS

There will be times that you need extra help and support. It's important to know that you don't have to go through this alone. Friends, family, social workers, and support groups are just some of the people around you that may help.

It may be hard to share your feelings with your caregiver, or to ask for help. Communication with your care partner is an important step in getting the support you need. The more they know how you're feeling, the better prepared they can be to help you.

Share more information and resources with your loved one by visiting TECENTRIQ.com/NSCLC/Caregiver.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg | 1200 mg
INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION ABOUT TECENTRIQ

What is the most important information about TECENTRIQ?

TECENTRIQ can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Lung problems

- cough
- shortness of breath
- chest pain

Intestinal problems

- diarrhea (loose stools) or more frequent bowel movements than usual
- stools that are black, tarry, sticky, or have blood or mucus
- severe stomach-area (abdomen) pain or tenderness

Liver problems

- yellowing of your skin or the whites of your eyes
- severe nausea or vomiting
- pain on the right side of your stomach area (abdomen)
- dark urine (tea colored)
- bleeding or bruising more easily than normal

Hormone gland problems

- headaches that will not go away or unusual headaches
- eye sensitivity to light
- eye problems
- rapid heartbeat
- increased sweating
- extreme tiredness
- weight gain or weight loss
- feeling more hungry or thirsty than usual
- urinating more often than usual
- hair loss
- feeling cold
- constipation
- your voice gets deeper
- dizziness or fainting
- changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

- decrease in your amount of urine
- blood in your urine
- swelling of your ankles
- loss of appetite

Continued on page 17.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1000 mg
INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION CONT.

Skin problems

- rash
- itching
- skin blistering or peeling
- painful sores or ulcers in mouth or nose, throat, or genital area
- fever or flu-like symptoms
- swollen lymph nodes

Problems can also happen in other organs.

These are not all of the signs and symptoms of immune system problems that can happen with TECENTRIQ. Call or see your healthcare provider right away for any new or worse signs or symptoms, including:

- Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
- Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
- Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
- Persistent or severe muscle pain or weakness, muscle cramps
- Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

- chills or shaking
- itching or rash
- flushing
- shortness of breath or wheezing
- dizziness
- feeling like passing out
- fever
- back or neck pain

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with TECENTRIQ. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with TECENTRIQ. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with TECENTRIQ if you have severe side effects.

Continued on page 18.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 2000 mg
INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION CONT.

Before you receive **TECENTRIQ**, tell your healthcare provider about all of your medical conditions, including if you:

- have immune system problems such as Crohn's disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to your chest area
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. **TECENTRIQ** can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with **TECENTRIQ**. **Females who are able to become pregnant:**
 - Your healthcare provider should do a pregnancy test before you start treatment with **TECENTRIQ**.
 - You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of **TECENTRIQ**.
- are breastfeeding or plan to breastfeed. It is not known if **TECENTRIQ** passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of **TECENTRIQ**.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of **TECENTRIQ when used alone include:**

- feeling tired or weak
- decreased appetite
- nausea
- cough
- shortness of breath

The most common side effects of **TECENTRIQ when used in lung cancer with other anti-cancer medicines include:**

- feeling tired or weak
- nausea
- hair loss
- constipation
- diarrhea
- decreased appetite

TECENTRIQ may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of **TECENTRIQ**. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of **TECENTRIQ**.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 2000 mg
INJECTION FOR IV USE

GLOSSARY

ALK (anaplastic lymphoma kinase) gene:

A gene that makes a protein called anaplastic lymphoma kinase (ALK), which may be involved in cell growth.

Antibody:

A protein made by the immune system during an immune response that attaches to specific cells and can affect the immune system's ability to target and kill cells.

EGFR (epidermal growth factor receptor):

The protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor.

Immune system:

A collection of organs, special cells, and substances that help protect you from infections and other diseases.

Infusion:

A method of putting fluids, including drugs, into the bloodstream. Also called intravenous infusion.

Median:

A statistics term. The middle value, or number, in a set of measurements, which have been put in order from lowest to highest.

Metastatic:

A stage in cancer where it has spread from the place where it started to other distant parts of the body.

NSCLC (non-small cell lung cancer):

A cancer that grows from inside your lungs or the lining of the airways.

Non-squamous lung cancer:

A type of lung cancer that does not start in early versions of squamous cells, which are flat cells that line the inside of the airways in the lungs.

PD-L1 (programmed death-ligand 1):

A protein found on the surface of many cells, including cancer cells, that can affect the immune system's ability to target and attack cells.

Protein:

A molecule that is the building block of the cells in the body. Proteins are needed for the body to function properly.

Source:

<http://www.cancer.gov/publications/dictionaries/cancer-terms>.

The people depicted herein are not actual patients.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 2000 mg
INJECTION FOR IV USE

NOTES

Use the following page to write down any notes, questions, or concerns you would like to mention to your healthcare team.



Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ**[®]
atezolizumab 840 mg / 2000 mg
INJECTION FOR IV USE

CAREGIVER SUPPORT

Thank you for taking an active role in your loved one's journey on TECENTRIQ[®] (atezolizumab). As a caregiver, you're a vital member of the team.

Access information and resources with your loved one by visiting TECENTRIQ.com/NSCLC/Caregiver



Please see full [Prescribing Information](#) and additional [Important Safety Information](#) throughout this brochure.

 **TECENTRIQ[®]**
atezolizumab 840 mg | 1200 mg
INJECTION FOR IV USE



For more information visit
TECENTRIQ.com/NSCLCinfo



or call the Patient Resource Center:
1 (877) GENENTECH (1-877-436-3683)

The Patient Resource Center is a general help line for questions related to TECENTRIQ for patients and caregivers and is not meant to be medical advice or replace the advice of your healthcare team.

Genentech
A Member of the Roche Group

© 2023 Genentech USA, Inc. All rights reserved.
M-US-00009694(v3.0)

 **TECENTRIQ**[®]
atezolizumab 840 mg / 1000 mg
INJECTION FOR IV USE